CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Blincyto for MRD-positive B-cell precursor ALL

Project Number PC0143-000
Brand Name Blincyto
Generic Name Blinatumomab
Tumour Type Leukemia
Indication Minimal residual disease (MRD)-positive B-cell precursor acute lymphoblastic leukemia (ALL)
Funding Request For the treatment of patients with minimal residual disease (MRD)-positive B-cell precursor ALL
Review Status Withdrawn
Clarification Amgen Canada Inc. has notified pCODR that the Category 2 submission requirements for the pre NOC submission of Blinatumomab (Blincyto) for MRD-positive B-cell precursor ALL cannot be met at this time. As per pCODR Procedures C3.1.6, the pCODR program has stopped the review.
Pre Noc Submission Yes
NOC Date
Manufacturer Amgen Canada Inc.
Sponsor Amgen Canada Inc.
Submission Date June 29, 2018
Submission Deemed Complete July 9, 2018
Submission Type Initial
Prioritization Requested Not Requested
Stakeholder Input Deadline ‡ July 16, 2018
Check-point meeting August 29, 2018
pERC Meeting (target date)
Initial Recommendation Issued (target date)
Feedback Deadline (target date) ‡
pERC Reconsideration Meeting (target date)
Final Recommendation Issued (target date)
Notification to Implement Issued

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.